Clinical Evaluation of DCB-WH1 in Healing of Chronic Diabetic Foot Ulcers
The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2011 by Oneness Biotech Co., Ltd..
Recruitment status was Recruiting
Recruitment status was Recruiting
Sponsor:
Oneness Biotech Co., Ltd.
Information provided by:
Oneness Biotech Co., Ltd.
ClinicalTrials.gov Identifier:
NCT00709514
First received: June 27, 2008
Last updated: March 3, 2011
Last verified: March 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The primary objective of this Phase 2 study is to evaluate the efficacy of DCB-WHI ointment in wound closure as compared to vehicle control when applied topically to chronic diabetic foot ulcers for 12 weeks. The secondary objective of this study is to collect safety information of DCB-WHI ointment.
This is a randomized, double-blind, parallel group, vehicle-controlled, multi-center study of DCB-WH1 ointment applied topically to grade 1 foot ulcers (according to Wagner grading system) in 50 subjects with diabetes mellitus.
| Condition | Intervention | Phase |
|---|---|---|
|
Chronic Diabetic Foot Ulcers |
Drug: DCB-WH1 ointment Drug: Placebo |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | A Phase II, Double-blind, Placebo-controlled Clinical Evaluation of DCB-WH1 in Healing of Chronic Diabetic Foot Ulcers |
Resource links provided by NLM:
Further study details as provided by Oneness Biotech Co., Ltd.:
Primary Outcome Measures:
- The incidence of complete ulcer closure [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 50 |
| Study Start Date: | May 2008 |
| Estimated Study Completion Date: | August 2011 |
| Estimated Primary Completion Date: | June 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 |
Drug: DCB-WH1 ointment
DCB-WH1 ointment (1.25%), topically applied twice daily
|
| Placebo Comparator: 2 |
Drug: Placebo
Placebo
|
Eligibility| Ages Eligible for Study: | 20 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Ages 20 or older with diabetes mellitus (Type 1 or 2) who has a cutaneous ulcer on the foot and present for at least 2 weeks
- The target ulcer is classified as a grade 1 ulcer according to a modified Wagner system, which includes wounds involving the epidermis, the dermis, the hypodermis or the subcutaneous fat but not the tendon or joint capsule. The thickness of aforesaid layers wounds be approximately between 0.2 mm and 8 mm and is ranging in size between 3 and 15 cm2 post debridement.
- An ankle brachial index ≥0.80.
- The study ulcer should show "infection control" as judged by the investigator
- The subject should be free of any necrotic or infected soft and bony tissue.
- Signed informed consent form.
Exclusion Criteria:
- Ulcers caused by venous or arterial insufficiency, osteomyelitis.
- Poor nutritional status (albumin < 3g/dl), poor diabetic control (HbA1c > 10%), anemia (hemoglobin<10 g/dL), a leukocyte counts < 1,000/cumm.
- Requiring prostaglandin treatment.
- Requiring treatment with corticosteroids, immunosuppressive or chemotherapeutic agents, radiotherapy.
- Presence of necrosis, purulence or sinus tracts that cannot be removed by debridement.
- Presence of connective tissue disease, renal failure (*eGFR≦30 ml/min/1.73m2), abnormal liver function (AST, ALT>2.5x upper limit of normal range), malignancy.
- vascularization surgery performed <8 weeks before entry in the study.
- A history of cerebrovascular events, coronary intervention (stent or coronary artery bypass graft (CABG)) or myocardial infarction, within 6 months prior to study.
- Female patient who has a positive pregnancy test or who is breastfeeding or unwilling to use appropriate contraceptive methods during study.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00709514
Contacts
| Contact: David Yeh, MS | +886-2-26558098 ext 306 | davidyeh@microbio.com.tw |
| Contact: Wennie Shih, MS | +886-2-26558098 ext 319 | wennie.shih@microbio.com.tw |
Locations
| Taiwan | |
| Clinical Research Division | Recruiting |
| Taipei, Taiwan, 115 | |
| Contact: David Yeh, Director +886-2-26558098 ext 306 davidyeh@microbio.com.tw | |
| Contact: Wennie Shih, Associate Project Manager +886-2-26558098 ext 319 wennie.shih@microbio.com.tw | |
| Principal Investigator: Low-Tong Ho, M.D. | |
| Sub-Investigator: Ching-Fai Kwok, M.D. | |
| Principal Investigator: Kuang-Chung Shih, PhD., MD. | |
| Sub-Investigator: Chih-Tsueng He, M.D. | |
| Sub-Investigator: Chieh-Hua Lu, M.D. | |
| Principal Investigator: Yu-Yao Huang, PhD., M.D. | |
| Sub-Investigator: Chih-Ching Wang, M.D. | |
| Sub-Investigator: Jui-Hung Sun, M.D. | |
| Principal Investigator: Chien-Ning Huang, PhD., M.D. | |
| Sub-Investigator: Wen-Chang Chen, M.D. | |
| Sub-Investigator: Yi-Sun Yang, M.D. | |
| Principal Investigator: Hsin-Chung Tsai, M.D. | |
| Sub-Investigator: Ming-Tse Chen, M.D. | |
| Principal Investigator: Wei-Chao Huang, M.D. | |
| Sub-Investigator: Yun-Shing Peng, M.D. | |
Sponsors and Collaborators
Oneness Biotech Co., Ltd.
Investigators
| Principal Investigator: | Low-Tong Ho, MD | Taipei Veterans General Hospital Taipei |
More Information
No publications provided
| Responsible Party: | Mr. Peter Pan/ Director, Clinical Research, Oneness Biotech Co., Ltd. |
| ClinicalTrials.gov Identifier: | NCT00709514 History of Changes |
| Other Study ID Numbers: | DCB-WH1-CP001 |
| Study First Received: | June 27, 2008 |
| Last Updated: | March 3, 2011 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Oneness Biotech Co., Ltd.:
|
Oneness DCB-WH1 DCB-WH1-CP001 chronic |
diabetic foot ulcers topical ointment |
Additional relevant MeSH terms:
|
Foot Diseases Ulcer Foot Ulcer Diabetic Foot Pathologic Processes Skin Diseases Leg Ulcer Skin Ulcer |
Diabetic Angiopathies Vascular Diseases Cardiovascular Diseases Diabetes Complications Diabetes Mellitus Endocrine System Diseases Diabetic Neuropathies |
ClinicalTrials.gov processed this record on May 19, 2013